v3.25.4
Note 4 - China Joint Venture
12 Months Ended
Dec. 31, 2025
Notes to Financial Statements  
Noncontrolling Interest Disclosure [Text Block]

NOTE 4.     CHINA JOINT VENTURE

 

In 2019, the Company executed a joint venture agreement with its Chinese supplier (the “China JV”) whereby the Company has a 51% ownership interest. The agreement required the Company to make capital contributions of approximately $357,000 into the newly formed entity, which were made in prior years. In June 2023, the Company executed an amendment to the joint venture agreement to increase the amount of its registered capital. The amendment requires the Company to make additional capital contributions to the China JV of $408,000, of which $214,000 has been made as of December 31, 2025. During May 2025, the China JV executed a distribution agreement with a Chinese distributor and commenced operations during the second quarter of 2025.

 

During 2024, the Company determined that the contributions made to the China JV to date are not sufficient for the China JV to fund expected losses without additional subordinated financial support. Accordingly, the Company has determined that the China JV is a VIE. The Company has determined that because it has the sole right to direct the activities of the China JV that most significantly impact its economic performance, and as the majority owner, has the obligation to absorb losses of the VIE and the right to receive benefits from the VIE that are significant to the China JV, that the Company is the primary beneficiary of the VIE. Accordingly, the China JV has been consolidated in these consolidated financial statements.

 

The China JV is organized as a limited liability company under the laws of the Peoples Republic of China, accordingly the Company's exposure to losses in the China JV is limited to the Company's registered capital in the Company, which is equal to the sum of the required capital contributions above. As the China JV is not currently sufficiently capitalized, the assets of the China JV are not available to settle obligations of the Company.

 

The following table summarizes the assets and liabilities of the China JV included in our consolidated balance sheets at December 31, 2025 and 2024, respectively:

 

  

Year Ended

 
  

December 31,

 

(In thousands)

 

2025

  

2024

 

Cash and cash equivalents

 $383  $13 

Trade accounts receivable

  213    

Inventories

  31    

Prepaid expenses and other current assets

  12   54 

Property and equipment, net

  225   247 
         

Accounts payable

  186   8 

Accrued expenses and other current liabilities

  63   33 

 

Changes in the Company’s ownership investment in the China JV were as follows:

 

  

Year Ended

 
  

December 31,

 

(In thousands)

 

2025

  

2024

 

Beginning interest in China JV

 $130  $229 

Contributions

  61    

Net income (loss) attributable to Apyx

  112   (99)

Ending interest in China JV

 $303  $130